Mass spectrometry used to test BTCC biomarkers
Biomarkers for bladder transitional cell carcinoma tested with mass spectrometry

GC, MDGC

Mass spectrometry used to test BTCC biomarkers

18 Apr, 2011

Published over 15 years ago. See the latest and most current information on GC, MDGC.

Scientists have tested potential biomarkers for bladder transitional cell carcinoma (BTCC).

Published in Proteome Science, the study was conducted by Hongjie Li, Changying Li, Huili Wu, Ting Zhang, Jin Wang, Shixin Wang and Jiwu Chang.

Known as one of the most common types of neoplasia in males, BTCC could be better tackled with urinary tumour biomarkers, the scientists suggest.

Samples from patients with low malignant and aggressive BTCC, as well as healthy subjects, were taken and tested using mass spectrometry and two-dimensional electrophoresis.

This revealed an increase in five proteins in patients suffering from either aggressive or low malignant BTCC.

Meanwhile, further testing illustrated that in cases of aggressive BTCC, the expression of Apo-A1 was "significantly increased".

"Taken together, our findings suggest Apo-A1 could be a potential biomarker related with early diagnosis and classification in two-tie grading system for bladder cancer," commented the team.

Proteome Science is an online journal that publishes open-access, peer-reviewed research.
 

Explore Our Other Sites

Labmate Online
ETH Zurich builds handheld device that detects fat burning from a single breath
Explore more Arrow
Envirotech Online
Designed for semiconductor. Proven across industries.
Explore more Arrow
Pollution Solutions Online
Oil pipeline decommissioning in Wales secures environmental safety for future generations
Explore more Arrow
Petro Online
Flash point testing aligned with petrochemical compliance requirements
Explore more Arrow